ANA CAROLINA PRADO RIBEIRO E SILVA

Índice h a partir de 2011
17
ResearcherID
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina

Filtros

Mostrar mais
Limpar filtros

Configurações

Assunto: Oncology ×

Resultados de Busca

Agora exibindo 1 - 10 de 20
  • article 34 Citação(ões) na Scopus
    Extranodal NK/T cell lymphoma, nasal type: An updated overview
    (2021) SANCHEZ-ROMERO, Celeste; BOLOGNA-MOLINA, Ronell; ALMEIDA, Oslei Paes de; SANTOS-SILVA, Alan Roger; PRADO-RIBEIRO, Ana Carolina; BRANDAO, Thais Bianca; CARLOS, Roman
    Extranodal NK/T-cell lymphoma, nasal type (ENKTCL-NT) is an aggressive malignancy associated with Epstein Barr virus infection, with a geographic and racial predilection for some Asian and Latin American countries. ENKTCL-NT manifests as a necrotic process affecting nasal or upper aerodigestive structures and, rarely, extranasal sites such as skin, and the gastrointestinal tract. ENKTCL-NT was characterized by its poor prognosis irrespective of clinical stage and therapy. However, during the last two decades, advances in its clinicopathologic, genetic and molecular characterization have been achieved, as have changes in the chemotherapy regimens that, in combination with radiotherapy, are significantly improving the survival of these patients, especially in initial stages. For these reasons, we present an overview of the historical background of ENKTCL-NT along with an updated review of its potential etiological factors, clinicopathologic and molecular features, as well as its prognostic models, current treatment protocols, and future directions on potential promising therapeutic approaches.
  • article 12 Citação(ões) na Scopus
    Impact of tumor site on the prognosis of salivary gland neoplasms: A systematic review and meta-analysis
    (2021) SANTOS, Erison Santana dos; RODRIGUES-FERNANDES, Carla Isabelly; SPEIGHT, Paul M.; KHURRAM, Syed Ali; ALSANIE, Ibrahim; NORMANDO, Ana Gabriela Costa; PRADO-RIBEIRO, Ana Carolina; BRANDAO, Thais Bianca; KOWALSKI, Luiz Paulo; GUERRA, Eliete Neves Silva; LOPES, Marcio Ajudarte; VARGAS, Pablo Agustin; SANTOS-SILVA, Alan Roger; LEME, Adriana Franco Paes
    In numerous types of cancer, the primary tumor site can show a correlation with disease behavior and survival outcomes. In salivary gland tumors (SGTs) this association remains controversial. This study assessed the association between primary sites of SGTs and prognosis. Studies from five databases were assessed and a metaanalysis was performed using studies that presented 95 % confidence interval (95 % CI), hazard ratio (HR) and survival analysis. Gathered information from 46,361 patients showed that site had a prognostic impact on SGTs. Tumors involving minor salivary glands showed worse overall survival (HR = 1.60; 95 % CI = 1.17-2.19; p = 0.003), disease-specific survival (HR=1.63; 95 % CI = 1.12-2.37; p = 0.01), and cause-specific survival (HR=2.10; 95 % CI = 1.72-2.55; p = 0.00001). Tumors from major salivary glands showed better recurrencefree survival (HR=2.31; 95 % CI = 1.77-3.02; p = 0.00001), and locoregional control of disease (HR=2.66; 95 % CI = 1.20-5.91; p = 0.02). Our results showed that the primary site of SGTs has an impact on patient prognosis.
  • article 17 Citação(ões) na Scopus
    Is photobiomodulation therapy effective in reducing pain caused by toxicities related to head and neck cancer treatment? A systematic review
    (2019) PAGLIONI, Mariana de Pauli; ALVES, Carolina Guimaraes Bonfim; FONTES, Elisa Kauark; LOPES, Marcio Ajudarte; RIBEIRO, Ana Carolina Prado; BRANDAO, Thais Bianca; MIGLIORATI, Cesar Augusto; SANTOS-SILVA, Alan Roger
    Photobiomodulation therapy (PBMT) has been considered an effective method for preventing and managing certain cancer-related toxicities in head and neck cancer (HNC) patients treated with radiotherapy and chemotherapy. However, the potential effects of PBMT on pain control and analgesia resulting from these toxicities is still controversial. The aim of this systematic review was to compile available evidence of the effects of PMBT on pain control and reduced use of analgesics in HNC patients. We searched three indexed databases: MEDLINE/PubMed, Embase, and Scopus. The databases were reviewed up to and including December 2018. Only human clinical studies in English language were selected. Information was only available for mucositis and radiodermatitis. Fifteen out of 1112 studies met the inclusion criteria (14 for oral mucositis (OM) and 1 for radiodermatitis). From the 14 studies involving the prevention and treatment of OM, 10 had the study subjects compared to a placebo group. Of these 10 studies, all but 1 showed statistically significant difference related to pain control favoring the PBMT group. The study that compared PBMT with other treatment modality showed better results in pain control with PBMT. It appears that PBMT application frequency and potency impact on pain control. The only study involving the prevention and treatment of radiodermatitis was compared to placebo arm and showed statistically significant difference related to pain control favoring the PBMT group. Seven studies compared the need of analgesic medication between PBMT and placebo groups. Of these, five studies showed that the use of analgesic medication was significantly higher in the placebo group. The current evidence supports that PBMT is effective in pain control resulting from OM and radiodermatitis and may also reduce the need for analgesics. The evidence is not yet available of the effects of PBMT in other HNC treatment-related toxicities.
  • article 51 Citação(ões) na Scopus
    Locally advanced oral squamous cell carcinoma patients treated with photobiomodulation for prevention of oral mucositis: retrospective outcomes and safety analyses
    (2018) BRANDAO, Thais Bianca; MORAIS-FARIA, Karina; RIBEIRO, Ana Carolina Prado; RIVERA, Cesar; SALVAJOLI, Joao Victor; LOPES, Marcio Ajudarte; EPSTEIN, Joel B.; ARANY, Praveen R.; CASTRO JR., Gilberto de; MIGLIORATI, Cesar Augusto; SANTOS-SILVA, Alan Roger
    The well-established clinical efficacy of photobiomodulation (PBM) therapy in management of oral mucositis (OM) is leading to increasing use in oncology care. This protection and enhanced repair of damage to mucosal tissue have led to the question of the potential effects of PBM therapy on pre-malignant and malignant cells. The purpose of this study was to examine the outcome of cancer therapy and incidence of tumor recurrence in locally advanced oral squamous cell carcinoma (OSCC) patients treated with PBM therapy for OM. A retrospective clinical analysis of 152 advanced OSCC patients treated with prophylactic PBM therapy for radiotherapy-induced OM from January 2009 to December 2014 was conducted. Of the 152 OSCC patients treated with PBM therapy in this study, 19 (12.5%) had stage III and 133 (87.5%) had stage IV tumors. Of these, 52 (34.2%) received initial treatment with surgery followed by adjuvant radiotherapy, 94 (61.8%) with exclusive chemoradiation, and 6 (4%) with induction chemotherapy followed by surgery and radiotherapy. After a mean follow-up of 40.84 (+/- 11.71) months, the overall survival and disease-free survival rates were 46.7 and 51.8%, respectively. Forty-five (29.6%) patients developed local-regional recurrence, 10 (6.57%) patients developed distant relapse, and 19 (12.5%) developed new (second) primary tumors. Clinicopathological features and survival outcomes in the PBM-treated patients were similar to previously published data for conventional treatments in patients with advanced OSCC. In this study, prophylactic use of PBM therapy did not impact treatment outcomes of the primary cancer, recurrence or new primary tumors, or survival in advanced OSCC patients.
  • article 33 Citação(ões) na Scopus
    Global prevalence of human papillomavirus-driven oropharyngeal squamous cell carcinoma following the ASCO guidelines: A systematic review and meta-analysis
    (2020) MARIZ, Bruno Augusto Linhares Almeida; KOWALSKI, Luiz Paulo; JR, William Nassib William; CASTRO, Gilberto de; CHAVES, Aline Lauda Freitas; SANTOS, Marcos; OLIVEIRA, Thiago Bueno de; ARAUJO, Anna Luiza Damaceno; NORMANDO, Ana Gabriela Costa; RIBEIRO, Ana Carolina Prado; BRANDAO, Thais Bianca; VARGAS, Pablo Agustin; LOPES, Marcio Ajudarte; SANTOS-SILVA, Alan Roger
    Objectives: to provide accurate information about the global prevalence of human papillomavirus (HPV) in oropharyngeal squamous cell carcinomas (OPSCC). Material and methods: a systematic review was performed using three main electronic databases. Studies were independently assessed by two reviewers based on established eligibility criteria, to identify the prevalence of HPV-driven OPSCC following criteria defined by the American Society of Clinical Oncology. Risk of bias was assessed using the Joanna Briggs Institute Critical Appraisal Checklist. Statistical software MedCalc was used to perform meta-analyses. Results: from 2215 records found, 15 were included, reporting data from 6009 patients (time period range: 1980-2016), distributed in 11 countries. Eleven studies were considered as presenting low risk, and four as moderate risk of bias. Using proportion meta-analysis, pooled prevalence of HPV-driven OPSCC was 44.8 % (95 %CI: 36.4-53.5 %; i(2) = 97.6 %), with the highest rates in New Zealand (74.5 %; 95 %CI: 60.9-85.3 %), and the lowest in Brazil (11.1 %; 95 %CI: 4.5-21.5 %). HPV prevalence was similar between males (45.7 %; 95 %CI: 36.5-55.0 %; i(2) = 96.4 %) and females (42.2 %; 95 %CI: 34.3- 50.5 %; i(2) = 85.4 %). Mean/median age ranged from 59.1-67.1 years in the HPV-negative group, and from 55.7-63.5 years in the HPV-positive group. There was an overall discordance between testing by p16 (49.4 %; 95 %CI, 38.2-60.5 %; i(2) = 96.2 %) and p16+ISH/PCR (44.7 %; 95 %CI, 33.5-56.2 %; i(2) = 96.4 %). Conclusion: Overall pooled prevalence of HPV-driven OPSCC was approximately 45 %, with similar distribution among males and females. Double p16/HPV-DNA/RNA testing may be considered to increase specificity and prognostic accuracy.
  • article 6 Citação(ões) na Scopus
    Strategic use of obturator prostheses for the rehabilitation of oral cancer patients during the COVID-19 pandemic
    (2021) BRANDAO, Thais Bianca; MIGLIORATI, Cesar Augusto; VECHIATO-FILHO, Aljomar Jose; SILVA, Wagner Gomes; RIBEIRO, Ana Carolina Prado; PARISE-JUNIOR, Orlando; KOWALSKI, Luiz Paulo; SANTOS-SILVA, Alan Roger
    During the current pandemic scenario, maxillofacial rehabilitation specialists involved with supportive care in cancer must transform its practice to cope with COVID-19 and improve protocols that could quickly return the oral function of complex cancer patients who cannot wait for surgical complex rehabilitation. This includes the role of the maxillofacial prosthodontist for the rehabilitation of surgically treated patients with maxillary cancers by the means of filling obturator prostheses that are considered an optimal scientific-based strategy to reduce hospital stay with excellent pain control, oral function (speech, swallowing, mastication, and facial esthetics), psychologic and quality of life outcomes for the patients following intraoral cancer resection. Therefore, the aim of this commentary was to bring new lights to the strategic use of obturator prostheses for the rehabilitation of oral cancer patients during the COVID-19 pandemic as well as to present a protocol for managing such cases.
  • article 7 Citação(ões) na Scopus
    Impact of pandemic COVID-19 outbreak on oral mucositis preventive and treatment protocols: new perspectives for extraoral photobiomodulation therapy
    (2020) FARIA, Karina Morais; GOMES-SILVA, Wagner; KAUARK-FONTES, Elisa; BONFIM-ALVES, Carolina Guimaraes; KOWALSKI, Luiz Paulo; PRADO-RIBEIRO, Ana Carolina; VECHIATO-FILHO, Aljomar Jose; LOPES, Marcio Ajudarte; MARTA, Gustavo Nader; JR, Gilberto de Castro; LEME, Adriana Franco Paes; MIGLIORATI, Cesar Augusto; SANTOS-SILVA, Alan Roger; BRANDAO, Thais Bianca
    This communication discusses the current challenges of oral mucositis (OM) management during the pandemic COVID-19 outbreak and reflects about an extraoral photobiomodulation protocol as an optimal alternative for preventing and treating OM in advanced cancer patients while minimizing the risk of infection by avoiding intraoral manipulation.
  • article 0 Citação(ões) na Scopus
    Impact of pandemic COVID-19 outbreak on oral mucositis preventive and treatment protocols: new perspectives for extraoral photobiomodulation therapy (vol 28, pg 4545, 2020)
    (2021) FARIA, Karina Morais; GOMES-SILVA, Wagner; KAUARK-FONTES, Elisa; BONFIM-ALVES, Carolina Guimaraes; KOWALSKI, Luiz Paulo; PRADO-RIBEIRO, Ana Carolina; VECHIATO-FILHO, Aljomar Jose; LOPES, Marcio Ajudarte; MARTA, Gustavo Nader; CASTRO JR., Gilberto de; LEME, Adriana Franco Paes; MIGLIORATI, Cesar Augusto; SANTOS-SILVA, Alan Roger; BRANDAO, Thais Bianca
  • article 0 Citação(ões) na Scopus
    Management of intraoral stents for radiotherapy during COVID-19 pandemic
    (2021) VECHIATO FILHO, Aljomar Jose; FARIA, Karina Morais; OLIVEIRA, Maria Cecilia Querido de; ANDRADE, Ariadne Padilha de; PRADO-RIBEIRO, Ana Carolina; SANTOS-SILVA, Alan Roger; WEE, Alvin G.; BRANDAO, Thais Bianca
    Radiotherapy is being performed in many situations as a curative approach for head and neck cancer instead of surgery due to the current novel coronavirus disease (COVID-19) pandemic. A recent publication reported that even hypofractionation was being conducted in order to reduce the daily exposure of both patients and the medical staff involved in cancer therapies. As a result, dental teams may be requested more frequently than usual to fabricate intraoral stents (IOS). Given that IOS may be a potential source of COVID-19 contagion, the main purpose of the present correspondence is to offer a guide on how health professionals may be safely presented in the room, on the management of the IOS and also how to sanitize the stents.
  • article 15 Citação(ões) na Scopus
    Integrative analysis to select cancer candidate biomarkers to targeted validation
    (2015) KAWAHARA, Rebeca; MEIRELLES, Gabriela V.; HEBERLE, Henry; DOMINGUES, Romenia R.; GRANATO, Daniela C.; YOKOO, Sami; CANEVAROLO, Rafael R.; WINCK, FlaviaV.; RIBEIRO, Ana Carolina P.; BRANDAO, Thais Bianca; FILGUEIRAS, Paulo R.; CRUZ, Karen S. P.; BARBUTO, Jose Alexandre; POPPI, Ronei J.; MINGHIM, Rosane; TELLES, Guilherme P.; FONSECA, Felipe Paiva; FOX, Jay W.; SANTOS-SILVA, Alan R.; COLETTA, Ricardo D.; SHERMAN, Nicholas E.; LEME, Adriana F. Paes
    Targeted proteomics has flourished as the method of choice for prospecting for and validating potential candidate biomarkers in many diseases. However, challenges still remain due to the lack of standardized routines that can prioritize a limited number of proteins to be further validated in human samples. To help researchers identify candidate biomarkers that best characterize their samples under study, a well-designed integrative analysis pipeline, comprising MS-based discovery, feature selection methods, clustering techniques, bioinformatic analyses and targeted approaches was performed using discovery-based proteomic data from the secretomes of three classes of human cell lines (carcinoma, melanoma and non-cancerous). Threeyfeature selection algorithms, namely, Beta-binomial, Nearest Shrunken Centroids (NSC), and Support Vector Machine-Recursive Features Elimination (SVM-RFE), indicated a panel of 137 candidate biomarkers for carcinoma and 271 for melanoma, which were differentially abundant between the tumor classes. We further tested the strength of the pipeline in selecting candidate biomarkers by immunoblotting, human tissue microarrays, label-free targeted MS and functional experiments. In conclusion, the proposed integrative analysis was able to pre-qualify and prioritize candidate biomarkers from discovery-based proteomics to targeted MS.